The Relationship Between Cumulative Platinum-Based Chemotherapy Dose And The Occurrence Of Ototoxicity In Head And Neck Malignancies
DOI:
https://doi.org/10.36408/mhjcm.v11i2.1085Keywords:
ototoxic, pure tone audiometry, chemotherapy, platinumAbstract
BACKGROUND: Chemotherapy is a treatment for head and neck malignancies. Hearing impairment is a side effect of chemotherapy, especially caused by platinum-based chemotherapy. Hearing impairment generally occurs at high frequencies after the administration of chemotherapy.
AIMS: To prove assosciation between cumulative doses of platinum-based chemotherapy and ototoxic events in head and neck malignancies.
METHOD: This is a cross-sectional study. The sample is patients with head and neck malignancy receiving platinum-based chemotherapy at Dr. Kariadi Hospital Semarang from March to June 2023. Hearing assessment using pure tone audiometry was performed randomly at all chemotherapy cycles. Data was analyzed with a chi-square test.
RESULT: Eighty-one subjects (52 male, 29 female), consisting of 71 subjects received cisplatin, and 10 subjects received carboplatin. Ototoxicity occurs in 91.7% of subjects receiving cumulative doses of cisplatin >300mg/m2 and carboplatin >1500mg/m2 compared to cumulative doses of cisplatin <300mg/m2 and carboplatin <1500mg/m2, which was 46.7% (p = 0.001, CI 1.416-2.725).
CONCLUSION: There was a significant association between cumulative doses of platinum-based chemotherapy and ototoxicity incidence of head and neck malignancy patients.
Downloads
References
1. Aupérin A. Epidemiology of head and neck cancers: an update. Curr Opin Oncol. 2020;32(3):178–86. DOI:10.1097/CCO.0000000000000629
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394–424. DOI:10.3322/caac.21492
3. To’bungan N, Aliyah SH, Wijayanti N, Fachiroh J. Epidemiologi, stadium, dan derajat diferensiasi kanker kepala dan leher. Biog J Ilm Biol. 2015;3:47–52. DOI:10.24252/bio.v3i1.566
4. Cohen N, Fedewa S, Chen AY. Epidemiology and Demographics of the Head and Neck Cancer Population. Oral Maxillofac Surg Clin North Am. 2018;30(4):381–95. DOI:10.1016/j.coms.2018.06.001
5. Rottenberg S, Disler C, Perego P. The rediscovery of platinum-based cancer therapy. Nat Rev Cancer. 2021;21(1):37–50. DOI:10.1038/s41568-020-00308-y
6. Dilruba S, Kalayda G V. Platinum-based drugs: past, present and future. Cancer Chemother Pharmacol. 2018;77(6):1103–24. DOI:10.1007/s00280-016-2976-z
7. Biro K, Noszek L, Prekopp P, Nagyiványi K, Géczi L, Gaudi I, et al. Characteristics and risk factors of cisplatin-induced ototoxicity in testicular cancer patients detected by distortion product otoacoustic emission. Oncology. 2006;70(3):177–84. DOI:10.1159/000093776
8. Monfared ZE, Khosravi A, Safavi Naini A, Radmand G, Khodadad K. Analysis of Cisplatin-Induced Ototoxicity Risk Factors in Iranian Patients with Solid Tumors: a Cohort, Prospective and Single Institute Study. Asian Pac J Cancer Prev. 2017;18(3):753–8. DOI:10.22034/APJCP.2017.18.3.753
9. Sriyapai T, Thongyai K, Phuakpet K, Vathana N, Buaboonnam J, Sanpakit K. Ototoxicity and long-term hearing outcome in pediatric patients receiving cisplatin. Turk J Pediatr. 2022;64(3):531–41. DOI:10.24953/turkjped.2021.5012
10. Edward ED, Rosdiana N, Farhat F, Siregar O, Lubis B. Prevalence and risk factors of hearing loss in children with solid tumors treated with platinum-based chemotherapy. Paediatr Indones. 2015;55(3 SE-Articles). DOI:10.14238/pi55.3.2015.121-5
11. Johnson DE, Burtness B, Leemans CR, Lui VWY, Bauman JE, Grandis JR. Head and neck squamous cell carcinoma. Nat Rev Dis Prim. 2020;6(1):92. DOI:10.1038/s41572-020-00224-3
12. Gormley M, Creaney G, Schache A, Ingarfield K, Conway DI. Reviewing the epidemiology of head and neck cancer: definitions, trends and risk factors. Br Dent J. 2022;233(9):780–6. DOI:10.1038/s41415-022-5166-x
13. Guo K, Xiao W, Chen X, Zhao Z, Lin Y, Chen G. Epidemiological Trends of Head and Neck Cancer: A Population-Based Study. Biomed Res Int. 2021;2021:1738932. DOI:10.1155/2021/1738932
14. Razzaghdoust A, Mofid B, Peyghambarlou P. Predictors of chemotherapy-induced severe anemia in cancer patients receiving chemotherapy. Support Care Cancer. 2020;28(1):155–61. DOI:10.1007/s00520-019-04780-7
15. Tang L-L, Chen Y-P, Chen C-B, Chen M-Y, Chen N-Y, Chen X-Z, et al. The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma. Cancer Commun (London, England). 2021;41(11):1195–227. DOI:10.1002/cac2.12218
16. Tsvetkova D, Ivanova S. Application of Approved Cisplatin Derivatives in Combination Therapy against Different Cancer Diseases. Molecules. 2022;27(8). DOI:10.3390/molecules27082466
17. Aguiar PNJ, Tadokoro H, da Silva GF, Landgraf MM, Noia Barreto CM, Filardi BA, et al. Definitive chemoradiotherapy for squamous head and neck cancer: cisplatin versus carboplatin? A meta-analysis. Future Oncol. 2016;12(23):2755–64. DOI:10.2217/fon-2016-0068
18. Patatt FSA, Gonçalves LF, Paiva KM de, Haas P. Ototoxic effects of antineoplastic drugs: a systematic review. Braz J Otorhinolaryngol. 2022;88(1):130–40. DOI: 10.1016/j.bjorl.2021.02.008
19. Apriliana C, Naftali Z, Yusmawan W. Decreased bone conduction value among nasopharing carcinoma with platinum based-cemotherapy: Combination of neoadjuvant paclitaxel-cisplatin and paclitaxel-carboplatin. J Kedokt Diponegoro. 2019;8(1). DOI:10.14710/dmj.v8i1.23300
20. Santosa YI, Samiadi D, Aroeman NA, Fianza PI. The effect of Tocoferol on Ototoxic effect of Cisplatin. Bandung Med J. 2012;44(4). DOI:10.15395/mkb.v44n4.176
21. Marcu LG. Gender and Sex-Related Differences in Normal Tissue Effects Induced by Platinum Compounds. Pharmaceuticals (Basel). 2022;15(2). DOI:10.3390/ph15020255
22. Argyriou AA, Polychronopoulos P, Koutras A, Iconomou G, Gourzis P, Assimakopoulos K, et al. Is advanced age associated with increased incidence and severity of chemotherapy-induced peripheral neuropathy? Support care cancer Off J Multinatl Assoc Support Care Cancer. 2006;14(3):223–9. DOI:10.1007/s00520-005-0868-6
23. Barginear M, Dueck AC, Allred JB, Bunnell C, Cohen HJ, Freedman RA, et al. Age and the Risk of Paclitaxel-Induced Neuropathy in Women with Early-Stage Breast Cancer (Alliance A151411): Results from 1,881 Patients from Cancer and Leukemia Group B (CALGB) 40101. Oncologist. 2019;24(5):617–23. DOI:10.1634/theoncologist.2018-0298
24. Mizrahi D, Park SB, Li T, Timmins HC, Trinh T, Au K, et al. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy. JAMA Netw open. 2021;4(2):e2036695. DOI:10.1001/jamanetworkopen.2020.36695
Additional Files
Published
How to Cite
Issue
Section
Citation Check
License
Copyright (c) 2024 Hendro Purnomo, Dwi Marliyanti, Muyassaroh, Dian Ayu Ruspita, Zulfikar Naftali (Author)
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
Copyrights Notice
Copyrights:
Researchers publishing manuscrips at Medica Hospitalis: Journal of Clinical Medicine agree with regulations as follow:
Copyrights of each article belong to researchers, and it is likewise the patent rights
Researchers admit that Medica Hospitalia: Journal of Clinical Medicine has the right of first publication
Researchers may submit manuscripts separately, manage non exclusive distribution of published manuscripts into other versions (such as: being sent to researchers’ institutional repository, publication in the books, etc), admitting that manuscripts have been firstly published at Medica Hospitalia: Journal of Clinical Medicine
License:
Medica Hospitalia: Journal of Clinical Medicine is disseminated based on provisions of Creative Common Attribution-Share Alike 4.0 Internasional It allows individuals to duplicate and disseminate manuscripts in any formats, to alter, compose and make derivatives of manuscripts for any purpose. You are not allowed to use manuscripts for commercial purposes. You should properly acknowledge, reference links, and state that alterations have been made. You can do so in proper ways, but it does not hint that the licensors support you or your usage.
